PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30649892-5	2019	Metformin counteracted glucose-dependent effects, and downregulated glutamate dehydrogenase, alanine aminotransferase, and mammalian target of rapamycin 5 h posttreatment in the absence of a glucose load, leading to decreased long-term activity of PFK1 and IDH.	Metformin	0-9	glutamic--pyruvic transaminase	Homo sapiens	93-117	
32023702-14	2020	The intracellular aspartate aminotransferase and alanine aminotransferase were decreased significantly after the treatment with low and high-dose metformin, which were (32.44 +- 4.08)U/L, (19.31 +- 3.03) U/L, (26.00 +- 3.11) U/L and (15.11 +- 4.11) U/L, respectively and the differences were statistically significant (P < 0.05).	Metformin	146-155	glutamic--pyruvic transaminase	Homo sapiens	49-73	
32072735-6	2020	In the full-study population, dapagliflozin plus saxagliptin plus metformin decreased body weight and serum alanine aminotransferase and aspartate aminotransferase levels over 52 weeks.	Metformin	66-75	glutamic--pyruvic transaminase	Homo sapiens	108-132	
30334569-5	2019	Metformin also significantly ( p < 0.05) inhibited TAA-induced HIF-1alpha, mTOR, the profibrogenic biomarker alpha-smooth muscle actin, tissue inhibitor of metalloproteinases-1, tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), alanine aminotransferase (ALT) and aspartate aminotransferase in harvested liver homogenates and blood samples.	Metformin	0-9	glutamic--pyruvic transaminase	Homo sapiens	241-265	
17718786-2	2007	We analyzed the data from this study to determine (a) if metformin reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) concentrations during the 6-month trial, and (b) if the response to pharmacotherapy varied along gender or ethnic lines.	Metformin	57-66	glutamic--pyruvic transaminase	Homo sapiens	81-105	
20186137-0	2010	Effects of metformin and weight loss on serum alanine aminotransferase activity in the diabetes prevention program.	Metformin	11-20	glutamic--pyruvic transaminase	Homo sapiens	46-70	
20186137-2	2010	We investigated whether metformin or changes in metabolic measurements (weight, fasting plasma glucose (FPG), or fasting insulin (FI)) improved serum alanine aminotransferase (ALT) activity, as a marker for NAFLD, in the Diabetes Prevention Program (DPP).	Metformin	24-33	glutamic--pyruvic transaminase	Homo sapiens	150-174